<DOC>
	<DOCNO>NCT00031785</DOCNO>
	<brief_summary>RATIONALE : Megestrol help improve appetite . It yet know megestrol effective limit weight loss patient undergoing radiation therapy . PURPOSE : Randomized phase III trial determine effectiveness megestrol limit weight loss patient undergoing radiation therapy lung cancer .</brief_summary>
	<brief_title>Megestrol Treating Patients Who Are Undergoing Radiation Therapy Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine effect megestrol weight patient receive radiotherapy lung cancer . - Determine quality life patient treated drug . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord histology ( non-small cell lung cancer v small cell lung cancer ) , type treatment ( radiotherapy v radiotherapy non-cisplatin-containing chemotherapy v radiotherapy cisplatin-containing chemotherapy ) . Patients randomize one two treatment arm . All patient undergo thoracic radiotherapy begin week 1 continue total 5-7 week . - Arm I : Patients receive oral megestrol daily begin within first 3 day radiotherapy continue 12 week completion radiotherapy . - Arm II : Patients receive oral placebo daily begin within first 3 day radiotherapy continue 12 week completion radiotherapy . In arm , quality life assess baseline , completion radiotherapy , 4 , 8 , 12 , 16 , 20 week completion radiotherapy . Patients follow 4 8 week . PROJECTED ACCRUAL : A total 98 patient ( 49 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lung cancer Unresectable stage IIIIB nonsmall cell lung cancer ( NSCLC ) Resected stage IIIIB NSCLC Limited stage small cell lung cancer Planned radiotherapy total dose least 5,000 cGy fraction size great 200 cGy No distant metastases No significant ascites , pleural effusion , edema would inhibit oral food intake invalidate weight determination PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Cardiovascular : No uncontrolled hypertension No active thromboembolic disease No myocardial infarction within past 3 month No prior congestive heart failure thromboembolic event Pulmonary : No prior pulmonary edema Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 3 year except curatively treat carcinoma situ cervix nonmelanoma skin cancer No uncontrolled diabetes glycosylated hemoglobin great 10 % No Cushing 's syndrome No dietary restriction ( e.g. , salt , sugar , lipid ) No serious medical psychiatric illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Endocrine therapy Endocrine therapy : At least 12 month since prior corticosteroid , estrogen , progestin , steroid hormone except antiemetic prior chemotherapy No concurrent corticosteroid , estrogen , progestin , steroid hormone except antiemetic prior chemotherapy Radiotherapy : See Disease Characteristics No prior radiotherapy lung Surgery : See Disease Characteristics More 14 day since prior surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>anorexia</keyword>
	<keyword>cachexia</keyword>
</DOC>